CONFERENCE UPDATES: ACC 2022

Mavacamten improves functional outcomes in patient with symptomatic obstructive HCM: The EXPLORER-LTE cohort of the MAVA-LTE study

CARDIOLOGY
29 Jun 2022

Get access to our exclusive articles.
Related Articles

Atorvastatin associated with reduced cardiac dysfunction in lymphoma patients treated with anthracycline: The STOP-CA trial
CARDIOLOGY
11 May 2023

Effects of sacubitril/valsartan to reduce NT-proBNP in HFrEF

NT-proBNP concentrations can more accurately reflect the status of HF patients who are undergoing treatment.1 According to recent findings from the PARAGON-HF trial, which was presented at the American College of Cardiology’s Annual Scientific Session 2020/World Congress of Cardiology (ACC20/WCC), NT-proBNP

CARDIOLOGY
30 Jun 2020

The MAVERICK HCM study: Safety and efficacy of mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy

There was a 53% decrease in the N-terminal (NT)-pro hormone BNP (NT-proBNP) (pooled mavacamten group; baseline: 713pg/mL) vs. a 1% decrease in the placebo group (baseline: 967pg/mL) (p=0.0005)

CARDIOLOGY
29 Jun 2020